Eli Lilly, Incyte Find Covid-19 Treatment Reduces Hospital Time
September 14 2020 - 7:12AM
Dow Jones News
By Matt Grossman
Eli Lilly & Co. and Incyte Corp. said Monday that their
trial of a treatment for Covid-19 successfully reduced the amount
of time it took for patients to recover.
In the trial of more than 1,000 patients, people hospitalized
with Covid-19 were given a 4-milligram dose of baricitinib plus
remdesivir. The treatment led to recoveries that were about one day
quicker, at the median, than those of patients who only got
remdesivir.
The National Institute of Allergy and Infectious Diseases, which
sponsored the trial, will publish the results in a journal, the
companies said.
Eli Lilly said it will discuss an emergency-use authorization
for 4-mg doses of baricitinib with the Food and Drug
Administration. In the U.S., the drug is already approved in 2-mg
doses to tread rheumatoid arthritis. Eli Lilly said the supply of
the drug for patients with that disease will remain adequate.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
September 14, 2020 06:57 ET (10:57 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2023 to Apr 2024
